Cat. No.: DAA-001109
Product Information | |
---|---|
Product Name | Human GLP-1 ELISA Kit |
Species | Human |
Description | Human GLP1 ELISA Kit is an in-vitro enzyme-linked immunosorbent assay for the quantitative measurement of Human GLP1 in serum, plasma and cell culture supernatants. This assay employs an antibody specific for Human GLP1 coated on a 96-well plate. Standards and samples are pipetted into the wells and Human GLP1 present in a sample is bound to the wells by the immobilized antibody. The wells are washed, and biotinylated anti-Human GLP1 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of Human GLP1 bound. |
Sample Types | Cell Culture Supernatant, Serum, Plasma |
Detection Range | 2.34 pg/mL - 150 pg/mL |
Sensitivity | 2.3 pg/mL |
Precision | CV: < 10% |
Target Information | |
---|---|
Target Name | GCG |
UniProt No. | P01275 |
Gene ID | 2641 |
Target Description | Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferaton. Inhibits beta cell apoptosis.GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life. |
Alternative Names | GCG; Glicentin related polypeptide; glicentin-related polypeptide; GLP-1; GLP-1(7-36); GLP-1(7-37); GLP-2; GLP1; GLP1, included; GLP2; GLP2, included; GLUC_HUMAN; Glucagon; Glucagon like peptide 1; glucagon-like peptide 1; Glucagon-like peptide 1, included; Glucagon-like peptide 2; Glucagon-like peptide 2, included; GRPP; OXM; OXY; preproglucagon |
Shipping & Storage | |
---|---|
Sipping | Shipping on dry ice. |
Storage | Store at -20°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.